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RCT Randomized controlled trial 
EFS Event-free survival 
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95%CI 95%-confidence interval 
VAC Vincristine dactinomycin cyclophosphamide 
VAI Vincristine dactinomycin ifosfamide 
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ABSTRACT 66 
Background: A marginal interaction between sex and the type of alkylating agent was 67 
observed for event-free survival in the Euro-EWING99-R1 randomized controlled trial (RCT) 68 
comparing cyclophosphamide and ifosfamide in Ewing sarcoma. To further evaluate this 69 
interaction, we performed an individual patient data meta-analysis of RCTs assessing 70 
cyclophosphamide vs. ifosfamide in any type of cancer. Methods: A literature search 71 
produced two more eligible RCTs (EICESS92 and IRS-IV). The endpoints were progression-72 
free survival (PFS, main endpoint) and overall survival (OS). The hazard ratios (HR) of the 73 
treatment-by-sex interaction and their 95%-confidence interval (95%CI) were assessed using 74 
stratified multivariable Cox models. Heterogeneity of the interaction across age categories 75 
and trials was explored. We also assessed this interaction for severe acute toxicity using 76 
logistic models. Results: The meta-analysis comprised 1528 pediatric and young adult 77 
sarcoma patients from three RCTs: Euro-EWING99-R1 (n=856), EICESS92 (n=155) and 78 
IRS-IV (n=517). There were 224 PFS events in Euro- EWING99-R1 and 200 in the validation 79 
set (EICESS92+IRS-IV); and 171 and 154 deaths in each dataset respectively. The estimated 80 
treatment-by-sex interaction for PFS in Euro-EWING99-R1 (HR=1.73, 95%CI=1.00-3.00) 81 
was not replicated in the validation set (HR=0.97, 95%CI=0.55-1.72), without heterogeneity 82 
across trials (p=0.62). In the pooled analysis, the treatment-by-sex interaction was not 83 
significant (HR=1.31, 95%CI=0.89-1.95, p=0.17), without heterogeneity across age 84 
categories (p=0.88) and trials (p=0.36). Similar results were observed for OS. No significant 85 
treatment-by-sex interaction was observed for leucopenia/neutropenia (p=0.45), infection 86 
(p=0.64) or renal toxicity (p=0.20). Conclusion: Our meta-analysis did not confirm the 87 
hypothesis of a treatment-by-sex interaction on efficacy or toxicity outcomes. 88 
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INTRODUCTION 89 
The Euro-E.W.I.N.G.99-R1 randomized trial (EE99-R1, NCT00020566)[1] compared the 90 
efficacy of cyclophosphamide and ifosfamide combined with vincristine and dactinomycin 91 
(VAC vs. VAI) as maintenance treatment in localized standard-risk Ewing sarcoma. We 92 
observed that sex marginally modified the treatment effect on event-free survival (EFS, 93 
interaction test, p=0.083): in males, VAC was associated with poorer EFS than VAI with a 94 
hazard ratio (HR) (VAC/VAI) =1.34 (95%CI, 0.96-1.86), whereas VAC was slightly better 95 
than VAI in females with a HR=0.83 (95%CI, 0.54-1.28).[2] 96 
Epidemiological studies have reported a higher incidence and mortality among men than 97 
women.[3,4] Registry-based survival analyses adjusted for age and disease stage have also 98 
shown that survival tends to be worse in males in various cancers.[4,5] Moreover, numerous 99 
clinical trials of cancer patients report a worse prognosis in males in most studies.[6–10] 100 
There are also sex differences in chemotherapy-related toxicity, especially with alkylating-101 
based chemotherapy, with higher toxicity rates in females, especially hematological 102 
toxicity.[2,10–14] Some of these findings regarding efficacy and toxicity can be explained by 103 
pharmacokinetic differences in drug metabolism (e.g. different expression of liver 104 
metabolizing enzymes according to sex), leading some authors to propose sex-based dose 105 
adaptations.[15–18] 106 
However, no interaction between the type of alkylating agent (cyclophosphamide or 107 
ifosfamide) and sex on efficacy and acute toxicity outcomes was reported before the EE99-R1 108 
trial. In an attempt to confirm the EE99-R1 observation, we conducted a Meta-Analysis on 109 
Interaction between Alkylating agents and GEnder (MAIAGE) of randomized controlled 110 
trials (RCT) comparing cyclophosphamide versus ifosfamide, to confirm whether or not the 111 
effect of these two treatments differs between males and females. 112 
 113 
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MATERIALS and METHODS 114 
Trial selection 115 
To identify an independent validation set for the EE99-R1 data, we undertook a bibliographic 116 
search of clinical trials randomizing cyclophosphamide vs. ifosfamide (possibly in addition to 117 
other drugs but these drugs had to be identical in both arms) in both sex, without restriction on 118 
patient age and type of cancer. We searched PubMed and The Cochrane Library for articles 119 
published between 1980 and 2013 (any language), and the National Institute of Health clinical 120 
trials register (https://clinicaltrials.gov/). In addition, all participating trialists were asked to 121 
review and supplement a provisional list of trials. Trial selection was accomplished by two 122 
authors (BF, GLT) and all relevant articles were reviewed by a third (MCLD). 123 
Cyclophosphamide and ifosfamide could have been administered either as a single drug or 124 
combined with other drugs, but in the latter case, the only difference between the two arms 125 
had to be cyclophosphamide and ifosfamide. Differences in the dosage and infusion duration 126 
of cyclophosphamide and ifosfamide were allowed across studies. RCTs comparing only one 127 
course of cyclophosphamide or ifosfamide were not eligible. Moreover RCTs for which 128 
individual patient data concerning survival and toxicity were not available, were excluded. 129 
 130 
Data extraction and trial quality assessment 131 
Individual patient data were collected for each trial: sex, date of birth, allocated treatment, 132 
date of randomization, date of first event, type of first event (progression, relapse, secondary 133 
malignancy, death), date of last follow-up or death, survival status and cause of death (if 134 
applicable). We also collected acute toxicity data for leucopenia/neutropenia, 135 
thrombocytopenia, infection, mucositis and diarrhea, renal, liver, cardiac, skin, central and 136 
peripheral neurologic toxicities during the randomized period with the grade according to the 137 
NCI-CTCAE (Common Terminology Criteria for Adverse Events) grading system. Individual 138 
anonymous data were centrally collected (BF, MCLD) and checked using a standard 139 
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procedure (See Supplemental Methods S1). We noted missing data, data validity, 140 
randomization integrity and follow-up of patients between the two arms.[19] 141 
 142 
Statistical analysis 143 
The primary endpoint was progression-free survival (PFS), defined as the time from 144 
randomization to progression, recurrence or death from any cause, whichever occurred first. 145 
The secondary endpoint was overall survival (OS), defined as the time from randomization to 146 
death from any cause. Patients who had no events were censored at the date of the last follow-147 
up. Analyses were performed on an intention-to-treat basis. 148 
The validation set was analyzed using a multivariable Cox model, stratified by trial and sex, 149 
and including treatment (cyclophosphamide vs. ifosfamide) and age as main fixed effects. 150 
Age was divided into 3 categories (< 12, [12-18] and > 18 years) with selected cut-offs close 151 
to those defining the different pubertal status for males and females. The hazard ratio (HR) of 152 
the treatment effect by sex was measured by an interaction term (“one-stage” model).[20] 153 
Sensitivity analyses were also performed (see Supplemental Methods S2). 154 
The heterogeneity test was assessed by Cochran’s Q-statistics and I².[21,22] In addition, we 155 
performed an exploratory analysis on all RCTs, i.e. EE99-R1 and the validation set. Stratified 156 
PFS curves were used to calculate the absolute difference at 5 years.[23] All statistical 157 
analyses performed for the validation set were also repeated on the pooled dataset. To explore 158 
heterogeneity of the treatment-by-sex interaction term across all trials and age categories, a 3-159 
order interaction term was included, with the relative 2-order interactions terms. 160 
For each type of acute toxicity, the maximum grade was computed for each patient and 161 
dichotomized as follows: hematologic toxicity (<, ≥grade-4), mucositis (<, ≥grade-3), 162 
diarrhea (<, ≥grade-3) and infection, renal, liver, cardiac, skin, central and peripheral 163 
neurologic toxicities (<, ≥grade-2). The main safety analysis included toxicities which had 164 
occurred in at least five males and females in each trial arm to allow interaction analyses: 165 
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leucopenia/neutropenia, infection, renal toxicity. For each type of toxicity, we estimated the 166 
treatment-by-sex interaction term using a logistic regression model stratified by trial and 167 
including age category, sex, treatment (main fixed effects) and treatment-by-sex interaction. 168 
We assessed the heterogeneity of the interaction across trials using a 3-order interaction term 169 
between treatment, sex and trial. 170 
All estimates are given with 95% confidence intervals (95%CI) and two-sided p-values. Data 171 
collection and statistical analyses were performed using SAS Software 9.3. Coxme and Meta 172 
R packages for R version 3.0.2 (http://www.R-project.org) were used respectively to perform 173 
Cox regression models with random treatment effects and forest plots. The results are 174 
reported according to PRISMA-IPD recommendations.[24] 175 
 176 
RESULTS 177 
Trials description 178 
In addition to the EE99-R1 trial[1], we identified three trials (EICESS92[25], IRS-IV[26] and 179 
an EORTC randomized phase-II trial in soft tissue sarcomas[27]) among 380 references of 180 
published papers and 37 studies registered on ClinicalTrials.gov (Figure-1). The EORTC trial 181 
was excluded because the individual patient data (survival and toxicity) were not available. 182 
We also excluded three randomized trials conducted exclusively in women (breast cancer[28], 183 
ovarian epithelial cancer[29] and endometrial adenocarcinoma[30]). Regarding the IRS-IV 184 
trial which compared three parallel groups, we considered the VAI and VAC arms, and 185 
excluded the third arm (vincristine-ifosfamide-etoposide arm). Actualization of the literature 186 
search in November 2016 did not identify any other trial fulfilling the inclusion criteria. 187 
The three RCTs retained were high-quality phase III trials (See Supplemental Methods S1) 188 
comparing cyclophosphamide to ifosfamide in multi-drug combinations administered as first-189 
line treatment (Table-1). Sex was considered as a stratification variable in these three trials. 190 
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The dose ratio of ifosfamide/cyclophosphamide ranged from 4 to 5. In total, 1528 patients 191 
were included, 773 in the cyclophosphamide arm and 755 in the ifosfamide arm. The EE99-192 
R1 trial represented 56% of the total number of patients. These trials were all conducted in 193 
sarcomas (Ewing sarcoma, rhabdomyosarcoma and undifferentiated sarcomas). They included 194 
children, adolescents and young adults, aged <15 years in 66% of the patients (Table-2). 195 
 196 
Survival analysis 197 
With a median follow-up of 6.8 years [Q1-Q3, 4.5-8.9] (5.9 and 8.0 years in EE99-R1 and the 198 
validation set containing EICESS92 and IRS-IV, respectively), we observed 424 disease 199 
failures (i.e. PFS events: 224 and 200 in EE99-R1 and the validation set, respectively; 200 
progression or relapse in 395 patients and death as first event in 29, including 6 treatment-201 
related deaths, 9 from disease progression, 9 other causes and 5 unknown causes). There were 202 
325 deaths overall (171 and 154 in EE99-R1 and the validation set, respectively). The 203 
estimated treatment-by-sex interaction on PFS in EE99-R1 (HR=1.73, 95%CI 1.00-3.00, p-204 
value=0.051) was not replicated in the validation set (n=672) using the one-stage model 205 
(EICESS92+IRS-IV, HR=0.97, 95%CI 0.55-1.72, p=0.93, Figure-2), with no heterogeneity 206 
between both trials (p=0.62). Interaction estimates were very similar in the sensitivity 207 
analyses (Table-3). In the same way, the estimated treatment-by-sex interaction in EE99-R1 208 
for OS (HR=1.85, 95%CI 0.98-3.48, p=0.056) was not replicated in the validation set 209 
(HR=1.00, 95%CI 0.52-1.92, p=0.99, Supplemental Figure-1).  210 
When the three RCTs were pooled, the estimated 5-year absolute PFS benefit associated with 211 
ifosfamide compared to cyclophosphamide was greater among males +6.0% (73.7% vs 212 
67.9%), than females (+0.2%, 75.2% vs 75.0%, Figure-3). However, the overall estimate of 213 
treatment-by-sex interaction was not statistically significant (HR=1.31, 95%CI 0.89-1.95, 214 
p=0.17). Although a significant treatment-by-sex interaction was observed in EE99-R1 215 
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(p=0.051), this interaction was not statistically different to interaction terms estimated in 216 
EICESS92 and IRS-IV trials (p=0.36, Figure-2). This interaction estimate did not vary across 217 
age categories (p=0.88, Supplemental Figure S2). The sensitivity analyses yielded similar 218 
results (last column, Table-3). For OS (Supplemental Figure S3), the pooled estimate of the 219 
treatment-by-sex interaction was not statistically significant (HR=1.37, 95%CI 0.87-2.15, 220 
p=0.17). We observed neither heterogeneity across trials (p=0.35, Figure-4) nor across age 221 
categories (p=0.64, Supplemental Figure S4). Stable results were observed in the sensitivity 222 
analyses (Table-3). 223 
 224 
Toxicity analysis 225 
The frequencies of severe acute toxicities by sex and treatment arm are shown in 226 
Supplemental Table S1. At least one episode of severe acute neutropenia, infection and renal 227 
toxicity had occurred in 69.8%, 52.8% and 7.8% of patients, respectively. As illustrated in 228 
Supplemental Figures S5-7, no significant interaction was identified between sex and 229 
alkylating agent for leucopenia/neutropenia (OR=0.82, 95%CI 0.49-1.36, p=0.43), infection 230 
(OR=1.11, 95%CI 0.71-1.71, p=0.65), or renal toxicity (OR=1.71, 95%CI 0.76-3.85, p=0.19). 231 
These estimates did not significantly vary across trials (heterogeneity tests for 232 
leucopenia/neutropenia: p=0.81, infection: p=0.12, and renal toxicity: p=0.19). The main 233 
effects were reported because no interaction was found between treatment and sex. Compared 234 
to ifosfamide, patients receiving cyclophosphamide experienced more severe 235 
leucopenia/neutropenia (ORcyclo vs ifo=1.47, 95%CI 1.14-1.88, p=0.003) and infections (ORcyclo 236 
vs ifo=1.55, 95%CI 1.25-1.93, p<0.0001), but less renal toxicity (ORcyclo vs ifo=0.71, 95%CI 237 
0.48-1.06, p=0.098). Regardless of treatment arm, females developed significantly more 238 
severe leucopenia/neutropenia (ORfemale vs male=1.39, 95%CI 1.08-1.79, p=0.013) and 239 
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infections (ORfemale vs male=1.25, 95%CI 1.01-1.56, p=0.041) than males, but not significantly 240 
more severe renal toxicity (ORfemale vs male=1.22, 95%CI 0.83-1.82, p=0.32). 241 
 242 
DISCUSSION 243 
Using an independent validation set of two RCTs (EICESS92 and IRS-IV), we did not 244 
replicate the treatment-by-sex interactions observed in the EE99-R1 trial on PFS and OS. No 245 
significant interactions were observed when the three trials were pooled, with no significant 246 
heterogeneity across age and trials. Similarly, we did not identify any treatment-by-sex 247 
interaction on leucopenia/neutropenia, infection and renal toxicity. Cyclophosphamide was 248 
significantly more hemato-toxic (leucopenia/neutropenia and infections) than ifosfamide. We 249 
also observed more hemato-toxicity in women than in males regardless of treatment arm. 250 
This individual patient data meta-analysis is the first to assess a potential interaction between 251 
the type of alkylating agent and sex. Based on high-quality RCTs comparing 252 
cyclophosphamide to ifosfamide in both sex, with a total number of patients exceeding 1, 500 253 
and long follow-up, it provides an unbiased estimate of the treatment-by-sex interaction. 254 
Finally, even though the search was not restricted to age or to a specific type of cancer, these 255 
three trials included mainly pediatric and young adult patients, with Ewing sarcoma or 256 
rhabdomyosarcoma under first-line treatment. This probably reduces sources of heterogeneity 257 
across trials (e.g. pharmacodynamic differences, co-morbidity, etc.). 258 
The EORTC trial [27] which randomized cyclophosphamide and ifosfamide as a single drug 259 
in advanced or metastatic soft-tissue sarcomas (n=135 patients) was not included in the 260 
MAIAGE study due to the lack of availability of individual survival or toxicity data after 261 
contacting the principal investigator. This study reported lower response rates in the 262 
cyclophosphamide arm than in the ifosfamide arm, especially in males (observed response 263 
rate of 0% and 11% in males treated with cyclophosphamide and ifosfamide, respectively, 264 
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and of 17% and 23% in females). Based on these data, we did not observe any significant 265 
heterogeneity of the treatment effect between sex (interaction test: p=0.12). In the three other 266 
randomized trials excluded (because they were based on women only, see Appendix) [28-30], 267 
a better prognosis was reported in two, in subgroups of women treated with ifosfamide 268 
[29,30] whereas the difference was not significant in the third trial.[28] 269 
Our study had some limitations. First, none of the trials analyzed were initially designed to 270 
study a treatment-by-sex interaction. Due to the observed number of events in each trial and 271 
when pooled, the analyses could be underpowered to test the interaction with a standard 272 
statistical level (p<0.05), let alone to detect heterogeneity of the treatment-by-sex interaction 273 
across trials (e.g. infection analysis with marginal heterogeneity across trials, p=0.12). 274 
Although we did not validate a treatment-by-sex interaction on efficacy outcomes, our results 275 
do not conclusively rule out the existence of an interaction. 276 
Second, in addition to the index trial, we identified only two other RCTs, which together 277 
contributed less than 50% of the total number of patients. We did not identify any other study 278 
comparing cyclophosphamide and ifosfamide, hence there is a paucity of independent trials. 279 
Finally, differences in population characteristics and in drug combinations in the backbone 280 
chemotherapy could impact the consistency of the estimates of treatment-by-sex interaction. 281 
Indeed, (i) rhabdomyosarcoma patients in IRS-IV were younger than Ewing sarcoma patients 282 
from the other two trials, and (ii) all IRS-IV patients received four additional courses with 283 
cyclophosphamide after the first eight courses allocated by randomization; in contrast, all 284 
patients also received ifosfamide as induction chemotherapy before randomization in both 285 
Ewing sarcoma trials. 286 
Our findings concerning acute toxicity are consistent with previous reports in sarcoma and 287 
lymphoma patients treated with alkylating agents.[10–14] Differences in cytochrome P450-288 
mediated drug metabolism between sex could explain these results. Cyclophosphamide and 289 
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ifosfamide are oxazaphosphorine alkylating prodrugs that are metabolized via different P450-290 
catalyzed pathways: (i) 4-hydroxylation produces active alkylating agents and urotoxic 291 
acrolein via CYP2B6 for cyclophosphamide and CYP3A4 and CYP3A5 for ifosfamide, and 292 
(ii) N-dechloroethylation generates inactive metabolites and nephro- and neuro-toxic 293 
chloroacetaldehyde via CYP3A4 for cyclophosphamide and, to a much greater extent,  294 
CYP3A4 and CYP2B6 for ifosfamide.[31–33] Greater activity of CYP3A4 and CYP2B6 has 295 
been reported in females resulting in higher concentrations of toxic chloroacetaldehyde after 296 
ifosfamide infusion and consequently in a possible higher risk of severe neurotoxicity in 297 
females.[34–36] However, no cytochrome P450-related difference in hematologic toxicity 298 
between sex has previously been reported. 299 
In conclusion, our meta-analysis did not show that the treatment effect of cyclophosphamide 300 
versus ifosfamide is influenced by sex, for either efficacy or toxicity. Therefore, 301 
recommending the choice of alkylating agent should not need be based on sex in children and 302 
young adults treated for sarcoma. Additional studies would be useful for long-term follow-up 303 
including fertility outcomes. 304 
  305 
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FIGURE LEGENDS 443 
 444 
Figure 1: Flow chart of trial selection process.  445 
 446 
C=Cyclophosphamide, I=Ifosfamide, STS=Soft tissue sarcoma. 447 
*The search strategy used the following search terms: "Ifosfamide"[Mesh] AND 448 
"Cyclophosphamide"[Mesh] AND ("Randomized Controlled Trial" [Publication Type] OR 449 
"Controlled Clinical Trial" [Publication Type]) in PubMed, "Ifosfamide” AND 450 
"Cyclophosphamide" in the Cochrane Library, and "Ifosfamide" AND "Cyclophosphamide" 451 
AND "Randomized" in the NIH clinical trials register (http://www.clinicaltrials.gov). 452 
Notes: Euro-EWING99-R1 trial was not yet published when we conducted the systematic 453 
review, that is why it does not appear in the initial systematic review box. Actualization of the 454 
literature search in November 2016 did not identify any other trial fulfilling the inclusion 455 
criteria. 456 
 457 
Figure 2: Forest plot of the hazard ratios (HR) of progression-free survival in the 458 
cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex using fixed effects 459 
model. 460 
 461 
The hazard ratios (HRs) given on the right side represent the HR of the treatment-by-sex 462 
interaction (HRCyclo/Ifo in males/ HRCyclo/Ifo in females) estimated independently for each 463 
trial, in the validation set and in the pooled dataset, by the one-stage model, stratified by trial 464 
and sex, and including treatment (cyclophosphamide vs. ifosfamide) and age (< 12, 12-18, 465 
and >18 years) as the main fixed effects. The heterogeneity of the interaction across trials was 466 
assessed using a 3-order interaction term. The center of each square represents the HR for 467 
individual trials and for the validation set (EICESS92 + IRS-IV) and the corresponding 468 
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horizontal line its 95% confidence interval (CI). The area of squares is proportional to the 469 
amount of information obtained from the trial. The center of the black diamond represents the 470 
overall HR and the extremities of the diamond represent its 95% CI, both estimated from the 471 
pooled dataset. 472 
 473 
Figure 3: Stratified progression-free survival (PFS) curves according to sex and 474 
alkylating agent (cyclophosphamide or ifosfamide) when the 3 RCTs were pooled 475 
(n=1528). 476 
 477 
The 5-year absolute PFS benefit associated with ifosfamide (Ifo) compared to 478 
cyclophosphamide (Cyclo) was estimated at 6% in males (73.7% vs. 67.9%), whereas females 479 
receiving ifosfamide or cyclophosphamide had similar PFS (75.2% vs. 75.0%, 480 
difference=0.2%). 481 
 482 
  483 
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SUPPLEMENTAL MATERIAL LEGENDS 484 
 485 
1. Supplementary methods 486 
Supplemental Methods S1: Procedure of data checking 487 
Supplemental Methods S2: Statistical methods for sensitivity analyses 488 
 489 
2. Supplementary results of survival analyses 490 
Supplemental Figure S1: Forest plot of the hazard ratios (HR) of death (overall 491 
survival) in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex 492 
using fixed effects models. 493 
Supplemental Figure S2: Forest plot of the hazard ratios (HR) of progression-free 494 
survival  in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex 495 
for each age category (<12 years, 12-18 years, >18 years) using fixed effects models 496 
when the 3 trials were pooled. 497 
Supplemental Figure S3: Stratified overall survival (OS) curves according to sex and 498 
alkylating agent (cyclophosphamide or ifosfamide) when the 3 trials were pooled. 499 
Supplemental Figure S4: Forest plot of the hazard ratios (HR) of overall survival in the 500 
cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex for each age 501 
category (<12 years, 12-18 years, >18 years) using fixed effects models when the 3 502 
trials were pooled. 503 
 504 
3. Detailed results of toxicity analyses 505 
Supplemental Table S1: Number of patients in each trial who experienced at least one 506 
episode of severe acute toxicity by sex and by treatment arm. 507 
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Supplemental Figure S5: Forest plot of the odd ratios (OR) of leucopenia/neutropenia 508 
in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex when the 509 
3 trials were pooled. 510 
Supplemental Figure S6: Forest plot of the odd ratios (OR) of infection in the 511 
cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex when the 3 512 
trials were pooled. 513 
Supplemental Figure S7: Forest plot of the odd ratios (OR) of renal toxicity in the 514 
cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) arm by sex when the 3 515 
trials were pooled. 516 
 517 
4. Description of the randomized controlled trials comparing alkylating agents, not 518 
included in the meta-analysis 519 
Supplemental Table S2: Information extracted from the 3 randomized trials conducted 520 
in women and not included in the meta-analysis 521 
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Figure 1: Flow chart of trial selection process.  
 
C=Cyclophosphamide, I=Ifosfamide, STS=Soft tissue sarcoma.  
*The search strategy used the following search terms: "Ifosfamide"[Mesh] AND "Cyclophosphamide"[Mesh] 
AND ("Randomized Controlled Trial" [Publication Type] OR "Controlled Clinical Trial" [Publication Type]) in 
PubMed, "Ifosfamide” AND "Cyclophosphamide" in the Cochrane Library, and "Ifosfamide" AND 
"Cyclophosphamide" AND "Randomized" in the NIH clinical trials register (http://www.clinicaltrials.gov).  
Notes: Euro-EWING99-R1 trial was not yet published when we conducted the systematic review, that is why 
it does not appear in the initial systematic review box. Actualization of the literature search in November 
2016 did not identify any other trial fulfilling the inclusion criteria.  
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Figure 2: Forest plot of the hazard ratios (HR) of progression-free survival in the cyclophosphamide (Cyclo) 
arm versus the ifosfamide (Ifo) arm by gender using fixed effects model.  
 
The hazard ratios (HRs) given on the right side represent the HR of the treatment-by-gender interaction 
(HRCyclo/Ifo in males/ HRCyclo/Ifo in females) estimated independently for each trial, in the validation set 
and in the pooled dataset, by the one-stage model, stratified by trial and gender, and including treatment 
(cyclophosphamide vs. ifosfamide) and age (< 12, 12-18, and >18 years) as the main fixed effects. The 
heterogeneity of the interaction across trials was assessed using a 3-order interaction term. The center of 
each square represents the HR for individual trials and for the validation set (EICESS92 + IRS-IV) and the 
corresponding horizontal line its 95% confidence interval (CI). The area of squares is proportional to the 
amount of information obtained from the trial. The center of the black diamond represents the overall HR 
and the extremities of the diamond represent its 95% CI, both estimated from the pooled dataset.  
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Figure 3: Stratified progression-free survival (PFS) curves according to gender and alkylating agent 
(cyclophosphamide or ifosfamide) when the 3 RCTs were pooled (n=1528).  
 
The 5-year absolute PFS benefit associated with ifosfamide (Ifo) compared to cyclophosphamide (Cyclo) was 
estimated at 6% in males (73.7% vs. 67.9%), whereas females receiving ifosfamide or cyclophosphamide 
had similar PFS (75.2% vs. 75.0%, difference=0.2%).  
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TABLE 1 Characteristics of selected randomized clinical trials with regimens comparing cyclophosphamide versus ifosfamide. 
 
 
 
N: number of randomized patients, Cyclo: cyclophosphamide, Ifo: Ifosfamide, CT : chemotherapy, VAI : vincristine, dactinomycin, ifosfamide, 
VAC: vincristine, dactinomycin, cyclophosphamide, VAIA: vincristine, dactinomycin, ifosfamide, adriamycin, VACA: vincristine, 
dactinomycin, cyclophosphamide, adriamycin, EFS: event-free survival, Q1: first quartile, Q3: third quartile. 
‡:  EWS: Ewing sarcoma, ESFT: Ewing sarcoma family of tumors, RMS: rhabdomyosarcoma.  
†: Intention to Treat. , w: week, y: year 
* patients with either a good histologic response to preoperative treatment (<10% cells), or a small tumor (< 200 mL) resected at diagnosis or 
with radiotherapy alone as local treatment. 
** after exclusion of patients with completely resected paratesticular tumors, completely resected or microscopic residual disease of orbit or 
eyelid tumors, pre-existing renal abnormalities. 
Trial
(ref)
 
Accrual 
period  
Type of trial  
and design 
N 
Median 
follow-up 
[Q1-Q3] 
Inclusion criteria 
Eligibility  criteria 
for randomization 
Randomized regimens 
Primary 
endpoint 
Results of 
ITT† analysis 
Pathology‡ 
Primary 
tumor site 
Age 
(years) 
Ifo 
(dose/3w) 
Cyclo  
(dose/3w) 
EE99-R1
(1)
 2000-2010 
Multicentric 
Phase III 
Non-
inferiority 
856 
5.9 
[3.8; 8.0] 
EWS 
Bone or soft 
tissue 
< 50 
Localized tumors 
With a good response 
to preoperative CT* 
7 VAI 
(3 g/m²x2)  
7 VAC 
(1.5 g/m²x1) 
3y-EFS 
78% (VAI) 
75% (VAC) 
EICESS92
(25)
 1992-1999 
Multicentric 
Phase III 
Non-
inferiority 
155 
8.3 
[6.9; 10.6] 
ESFT Bone < 35 
Localized tumors of less 
than 100mL 
10 VAIA 
(2 g/m²x3) 
10 VACA 
(1.2 g/m²x1) 
3y-EFS 
74% (VAIA) 
73% (VACA) 
IRS-IV(26) 1991-1997 
Multicentric 
Phase III 
Superiority 
517 
8.0 
[5.5; 9.9] 
RMS, 
undifferentiated 
sarcoma 
Soft tissue < 21 Localized tumors** 
8 VAI ◊ 
(1.8 g/m²x5) 
8 VAC 
(2.2 g/m²x1) 
3y-EFS 
77% (VAI) 
73% (VAC) 
Page 26 of 41Pediatric Blood & Cancer
TABLE 2 Characteristics of randomized patients in each trial included in the meta-analysis. 
 
 
 EE99-R1 EICESS92 IRS-IV Pooled dataset 
 
VAI 
(n=425) 
VAC 
(n=431) 
VAIA 
(n=76) 
VACA 
(n=79) 
VAI 
(n=254) 
VAC 
(n=263) 
Ifo arm 
(n=755) 
Cyclo arm 
(n=773) 
Sex         
   - male 251 258 46 49 141 152 438 459 
   - female 174 173 30 30 113 111 317 314 
Age (years)         
   Median 14.0 14.6 15.4 13.8 6.0 5.0 11.8 12.0 
   [0 ; 10[ 120 99 17 18 172 190 309 307 
   [10 ; 15[ 127 127 19 31 54 39 200 197 
   [15 ; 20[ 88 107 23 17 28 32 139 156 
   ≥20 90 98 17 13  2 107 113 
Pathology         
   - ESFT 415 416 73 77   488 493 
   - RMS     234 248 234 248 
   - Other bone sarcoma 1 1 1    2 1 
   - Other STS 10 14 2 2 20 15 32 31 
Tumor stage         
   - Localized disease 425 430 72 78 244 253 741 761 
   - Metastatic disease  1 3 1   3 2 
   - NA   1  10 10 11 10 
Number of events 106 118 28 28 62 82 196 228 
   - Progression/relapse 102 115 27 27 55 69 184 211 
   - Death as first event 4 3 1 1 7 13 12 17 
Number of deaths 83 88 18 21 51 64 152 173 
 
VAI: vincristine, dactinomycin, ifosfamide, VAC: vincristine, dactinomycin, cyclophosphamide, VAIA: vincristine, dactinomycin, ifosfamide, 
adriamycin, VACA: vincristine, dactinomycin, cyclophosphamide, adriamycin, Ifo: ifosfamide, Cyclo: cyclophosphamide, CT: chemotherapy, 
ESFT: Ewing sarcoma family of tumors, RMS: rhabdomyosarcoma, STS: soft tissue sarcoma, NA: not applicable. 
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TABLE 3 Estimate of the hazard ratio of the treatment-by-gender interaction term for 
progression-free survival and overall survival for EE99-R1 (training set), EICESS92 + 
IRS-IV (validation set) and the pooled dataset in the main and sensitivity analyses. 
 
 
Training set 
EE99-R1 
(n=856) 
Validation set 
EICESS92 + IRS-IV 
(n=672) 
Pooled analysis 
EE99-R1 + EICESS92 + IRS-IV 
(n=1528) 
 
HR (95%CI) HR (95%CI) HR (95%CI) 
Progression-free survival 
   
- Main analysis: OSM, fixed effects, age category 1.73 (1.00-3.00), p=0.051 0.97 (0.55-1.72), p=0.93 1.31 (0.89;1.95), p=0.17 
- Sensitivity analyses 
   
* OSM, random effects, age category 1.73 (1.00-3.00), p=0.051 0.98 (0.55-1.73), p=0.93 1.32 (0.89;1.95), p=0.17 
* OSM, fixed effects, age continuous 1.71 (0.98-2.96), p=0.057 0.96 (0.55-1.71), p=0.90 1.31 (0.89-1.95), p=0.17 
* PWT, fixed effects, age category 
 
0.97 (0.55-1.73), p=0.92 1.32 (0.88;1.96), p=0.18 
    
Overall survival 
   
- Main analysis: OSM, fixed effects, age category 1.85 (0.98-3.48), p=0.056 1.00 (0.52-1.92), p=0.99 1.37 (0.87;2.15), p=0.17 
- Sensitivity analyses 
   
* OSM, random effects, age category 1.85 (0.98-3.48), p=0.056 1.00 (0.52-1.93), p=1.00 1.37 (0.87;2.16), p=0.17 
* OSM, fixed effects, age continuous 1.80 (0.96-3.38), p=0.068 0.99 (0.51-1.91), p=0.98 1.37 (0.87;2.16), p=0.17 
* PWT, fixed effects, age category 
 
0.99 (0.51-1.91), p=0.98 1.37 (0.87;2.16), p=0.17 
 
HR: hazard ratio of the treatment-by-gender interaction term (HR Cyclo vs. Ifo in males / HR 
Cyclo vs. Ifo in Females) 
95%CI: 95% Confidence Interval 
OSM: one-stage model; PWT: pooling of within-trial covariate interactions model; age 
category: <12 years, [12-18] years and >18 years 
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Supplementary material 
 
1. Supplementary methods 
Supplemental Methods S1: Procedure of data checking 
Supplemental Methods S2: Statistical methods for sensitivity analyses 
 
2. Supplementary results of survival analyses 
 
3. Detailed results of toxicity analyses 
 
4. Description of the randomized controlled trials comparing alkylating agents, not 
included in the meta-analysis 
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1. Supplementary methods 
 
Supplemental Methods S1: Procedure of data checking 
We have checked the data according to a standardized procedure1. Missing values and 
discrepancies were discussed with the trialists. Randomization validity was assessed by 
checking the patterns of treatment allocation and the balance in baseline characteristics 
between treatment groups. Definition of population set was evaluated for each trial to perform 
the meta-analysis according to the intention-to-treat principle. Patients follow-up was also 
compared between treatment groups. Each trial was then reanalyzed and the analyses were 
sent to the trialists for validation. 
 
A. Randomization validity 
Curves representing cumulative accrual were plotted and compared between treatment arms: 
no bias was observed. Among the selected trials, an imbalance between the baseline 
characteristics of the treatment arms was not detected (See Table 2).  
 
B. Definition of the population sets 
Respect of the intention-to-treat principle was requested for randomized trials even if some 
patients were excluded in the initial analyses of the trial. Overall, 65 randomized patients had 
been excluded in the initial trial publications, all in the IRS-IV trial. These 65 patients were 
included in the meta-analysis. 
 
                                                           
1
 Stewart LA, Clarke MJ on behalf of the Cochrane Working Group on meta-analyses using 
individual patient data. Practical methodology of meta-analyses (overviews) using updated 
individual patients data. Stat Med 1995;14:2057-2079. 
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C. Follow-up 
For each treatment arm, reverse Kaplan-Meier curves were plotted: no bias was observed. 
Median follow-up was 6.8 years [Q1:4.5; Q3:8.9] in the pooled dataset and there was no 
difference between treatment arms within each trial (EE99-R1: 5.9 and 6.0 for VAC and VAI, 
respectively. EICESS92: 8.2 and 8.3 for VAIA and VACA, respectively. IRS-IV: 7.7 and 8.1 
for VAI and VAC, respectively). 
 
Supplemental Methods S2: Statistical methods for sensitivity analyses 
Several pre-specified sensitivity analyses were performed: 
(i) The addition of a study-specific random component for the treatment effect in the one-
stage method (OSM); 
(ii) The impact of a misspecification of age was evaluated by including age as a 
continuous covariate in the OSM; 
(iii) We used the “two-stage” approach to assess the overall treatment-by-sex interaction 
(“pooling within-trial covariate interactions” method, PWT).[20] We estimated interaction 
coefficients independently within each trial using multivariable Cox regression models, and 
then pooled them using the inverse-variance technique with fixed effects.[37] 
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1. Supplementary results of survival analyses 
 
Supplemental Figure S1: Forest plot of the hazard ratios (HR) of death (overall survival) in the cyclophosphamide (Cyclo) arm versus 
the ifosfamide (Ifo) arm by sex using fixed effects models. 
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Supplemental Figure S2: Forest plot of the hazard ratios (HR) of progression-free survival  in the cyclophosphamide (Cyclo) arm versus 
the ifosfamide (Ifo) arm by sex for each age category (<12 years, 12-18 years, >18 years) using fixed effects models when the 3 trials were 
pooled. 
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Supplemental Figure S3: Stratified overall survival (OS) curves according to sex and 
alkylating agent (cyclophosphamide or ifosfamide) when the 3 trials were pooled.  
 
 
 
 
The 5-year absolute OS benefit associated with ifosfamide (Ifo) compared to 
cyclophosphamide (Cyclo) was estimated at +2.2% in males (79.7% vs. 77.5%) and -1.1% in 
females (80.4% vs. 81.5%). 
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Supplemental Figure S4: Forest plot of the hazard ratios (HR) of overall survival in the cyclophosphamide (Cyclo) arm versus the 
ifosfamide (Ifo) arm by sex for each age category (<12 years, 12-18 years, >18 years) using fixed effects models when the 3 trials were 
pooled. 
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2. Detailed results of toxicity analyses 
Supplemental Table S1: Number of patients in each trial who experienced at least one 
episode of severe acute toxicity by sex and by treatment arm. 
Acute toxicity Sex Treatment 
Number of patients with acute toxicity / number of patients with 
available information (%) 
EE99-R1 (n=814) EICESS92 (n=129) IRS-IV (n=486) 
Leucopenia/neutropenia 
Female 
VAC 131 / 152 (86.2) 14 / 25 (56.0) 75 / 106 (70.8) 
VAI 124 / 155 (80.0) 12 / 25 (48.0) 67 / 105 (63.8) 
Male 
VAC 181 / 234 (77.4) 16 / 40 (40.0) 90 / 142 (63.4) 
VAI 161 / 225 (71.6) 10 / 37 (27.0) 81 / 133 (60.9) 
Infection 
Female 
VAC 90 / 161 (55.9) 13 / 25 (52.0) 73 / 106 (68.9) 
VAI 89 / 161 (55.3) 9 / 25 (36.0) 56 / 105 (53.3) 
Male 
VAC 127 / 246 (51.6) 20 / 40 (50.0) 87 / 142 (61.3) 
VAI 88 / 240 (36.7) 15 / 37 (40.5) 75 / 133 (56.4) 
Renal toxicity* 
Female 
VAC 8 / 160 (5.0) 5 / 24 (20.8) 5 / 106 (4.7) 
VAI 22 / 160 (13.8) 6 / 25 (24.0) 5 / 105 (4.8) 
Male 
VAC 13 / 246 (5.3) 9 / 40 (22.5) 7 / 142 (4.9) 
VAI 12 / 239 (5.0) 5 / 38 (13.2) 13 / 133 (9.8) 
Thrombocytopenia 
Female 
VAC 79 / 161 (49.1) 4 / 25 (16.0) 57 / 106 (53.8) 
VAI 72 / 161 (44.7) 0 / 25 (0.0) 38 / 105 (36.2) 
Male 
VAC 102 / 245 (41.6) 4 / 40 (10.0) 70 / 142 (49.3) 
VAI 64 / 241 (26.6) 1 / 37 (2.7) 36 / 133 (27.1) 
Mucositis 
Female 
VAC 6 / 160 (3.8) 3 / 25 (12.0) 59 / 106 (55.7) 
VAI 6 / 160 (3.8) 0 / 24 (0.0) 40 / 105 (38.1) 
Male 
VAC 5 / 246 (2.0) 3 / 39 (7.7) 50 / 142 (35.2) 
VAI 5 / 240 (2.1) 2 / 37 (5.4) 55 / 133 (41.4) 
Diarrhea 
Female 
VAC 1 / 160 (0.6) 1 / 12 (8.3) 18 / 106 (17.0) 
VAI 5 / 160 (3.1) 0 / 14 (0.0) 9 / 105 (8.6) 
Male 
VAC 4 / 246 (1.6) 1 / 23 (4.3) 18 / 142 (12.7) 
VAI 1 / 240 (0.4) 0 / 26 (0.0) 12 / 133 (9.0) 
Liver toxicity 
Female 
VAC 7 / 160 (4.4) 1 / 25 (4.0) 15 / 106 (14.2) 
VAI 11 / 159 (6.9) 2 / 24 (8.3) 9 / 105 (8.6) 
Male 
VAC 15 / 245 (6.1) 3 / 38 (7.9) 23 / 142 (16.2) 
VAI 9 / 239 (3.8) 0 / 37 (0.0) 8 / 133 (6.0) 
Central  
neurologic toxicity 
Female 
VAC 1 / 160 (0.6) 2 / 24 (8.3) 5 / 106 (4.7) 
VAI 4 / 160 (2.5) 0 / 24 (0.0) 7 / 105 (6.7) 
Male 
VAC 2 / 244 (0.8) 0 / 39 (0.0) 7 / 142 (4.9) 
VAI 3 / 240 (1.3) 0 / 36 (0.0) 6 / 133 (4.5) 
Peripheral neurologic 
toxicity 
Female 
VAC 11 / 159 (6.9) 3 / 25 (12.0) 26 / 106 (24.5) 
VAI 15 / 159 (9.4) 1 / 24 (4.2) 25 / 105 (23.8) 
Male 
VAC 17 / 245 (6.9) 3 / 39 (7.7) 35 / 142 (24.6) 
VAI 8 / 240 (3.3) 2 / 37 (5.4) 34 / 133 (25.6) 
Cardiac toxicity 
Female 
VAC 3 / 133 (2.3) 5 / 23 (21.7) 2 / 106 (1.9) 
VAI 9 / 143 (6.3) 4 / 22 (18.2) 2 / 105 (1.9) 
Male 
VAC 6 / 210 (2.9) 8 / 36 (22.2) 3 / 142 (2.1) 
VAI 6 / 208 (2.9) 8 / 33 (24.2) 1 / 133 (0.8) 
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VAI: vincristine, dactinomycin, ifosfamide, VAC: vincristine, dactinomycin, 
cyclophosphamide  
Adverse events were evaluated using the NCI CTCAE-v2 scale in the EE99-R1 and EICESS92 
trials, and NCI CTCAE-v1 scale in the IRS-IV trial. 
*Severe renal toxicity (grade 2 or more): at least one episode of increased plasmatic creatinine 
> 1.5 baseline, or a glomerular filtration rate decrease <60ml/min/1.73m² or a tubular phosphate 
reabsorption decrease <80%. 
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Supplemental Figure S5: Forest plot of the odd ratios (OR) of leucopenia/neutropenia in the cyclophosphamide (Cyclo) arm versus the 
ifosfamide (Ifo) arm by sex when the 3 trials were pooled.  
 
The Odd Ratios (ORs) given on the right side represent the OR of the treatment-by-sex interaction (ORCyclo/Ifo in males/ ORCyclo/Ifo in females) estimated 
independently for each trial and in the pooled dataset, using the logistic regression model, stratified by trial and sex, and including treatment 
(cyclophosphamide vs. ifosfamide) and age (< 12, 12-18, and >18 years) as the main fixed effects. Heterogeneity of the interaction (treatment x 
sex) across trials was assessed using the 3-order interaction term. 
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Supplemental Figure S6: Forest plot of the odd ratios (OR) of infection in the cyclophosphamide (Cyclo) arm versus the ifosfamide (Ifo) 
arm by sex when the 3 trials were pooled.  
 
 
  
Page 39 of 41 Pediatric Blood & Cancer
12 
 
Supplemental Figure S7: Forest plot of the odd ratios (OR) of renal toxicity in the cyclophosphamide (Cyclo) arm versus the ifosfamide 
(Ifo) arm by sex when the 3 trials were pooled. 
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3. Description of the randomized controlled trials comparing alkylating agents, not included in the meta-analysis 
Supplemental Table S2: Information extracted from the 3 randomized trials conducted in women and not included in the meta-analysis 
Author Pathology Treatment arms 
Number of 
patients 
Response rate 
(CR or PR) 
Progression-free survival (PFS)‡ 
Overall survival 
(OS) 
Buzdar 
[28] 
Breast carcinoma 
FAC+BCG+levamisole 117 72.6% 
Median time to progression: 
17 months 
Median OS: 
21.4 months 
FAI+BCG+levamisole 49* 65.3% 
Median time to progression: 
17.8 months 
Median OS: 
23.5 months 
Nishida 
[29] 
Ovarian epithelial cancer 
PAC 53 NA 
3y-PFS: 
84.9% 
5y-PFS: 
79.0% 
10y-PFS: 
67.8% 
NA 
PAI 52 NA 
3y-PFS: 
88.5% 
5y-PFS: 
88.5% 
10y-PFS: 
81.1% 
NA 
Pawinski 
[30] 
Adenocarcinoma of 
uterine corpus 
Cyclo 29 6.9% 
Median time to progression:  
7 weeks 
NA 
Ifo 32 12.5% 
Median time to progression:  
8 weeks 
NA 
 
FAC: 5-fluorouracil, adriamycin, cyclophosphamide, FAI: 5-fluorouracil, adriamycin, cyclophosphamide, PAC: cisplatin, epirubicin, 
cyclophosphamide, PAI: cisplatin, epirubicin, ifosfamide, Cyclo: cyclophosphamide, Ifo: ifosfamide, CR: complete response, PR: partial 
response, NA: not available 
* The FAI arm was closed because of increased bladder toxicity observed with ifosfamide resulting in a greater number of patients in the FAC 
arm. 
‡: no information on the precision of the estimate (standard error, confidence interval or number of at-risk patients) was reported. 
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